BR112017009854A2 - composto, uso de um composto, e, método para tratamento de leucemia. - Google Patents

composto, uso de um composto, e, método para tratamento de leucemia.

Info

Publication number
BR112017009854A2
BR112017009854A2 BR112017009854-7A BR112017009854A BR112017009854A2 BR 112017009854 A2 BR112017009854 A2 BR 112017009854A2 BR 112017009854 A BR112017009854 A BR 112017009854A BR 112017009854 A2 BR112017009854 A2 BR 112017009854A2
Authority
BR
Brazil
Prior art keywords
compound
treating leukemia
leukemia
treating
formula
Prior art date
Application number
BR112017009854-7A
Other languages
English (en)
Other versions
BR112017009854B1 (pt
Inventor
ERIKSSON Helena
Svensson Leif
Törngren Marie
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR112017009854A2 publication Critical patent/BR112017009854A2/pt
Publication of BR112017009854B1 publication Critical patent/BR112017009854B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de leucemia.
BR112017009854-7A 2014-11-19 2015-11-05 Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia BR112017009854B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193776 2014-11-19
EP14193776.3 2014-11-19
PCT/EP2015/075769 WO2016078921A1 (en) 2014-11-19 2015-11-05 Quinoline carboxamides for use in the treatment of leukemia

Publications (2)

Publication Number Publication Date
BR112017009854A2 true BR112017009854A2 (pt) 2018-01-16
BR112017009854B1 BR112017009854B1 (pt) 2022-08-23

Family

ID=51951635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009854-7A BR112017009854B1 (pt) 2014-11-19 2015-11-05 Uso do composto 4-hidroxi-5-metoxi-n,1-dimetil-2-oxo-n-[4-(trifluorometil)fenil]-1,2-dihidroquinolina-3-carboxamida (tasquinimod) ou um sal farmaceuticamente aceitável do mesmo para o tratamento de leucemia

Country Status (15)

Country Link
US (1) US10300053B2 (pt)
EP (1) EP3180005B1 (pt)
JP (1) JP6715833B2 (pt)
KR (1) KR102525805B1 (pt)
CN (1) CN107072989B (pt)
AU (1) AU2015348778B2 (pt)
BR (1) BR112017009854B1 (pt)
CA (1) CA2967112C (pt)
EA (1) EA031643B1 (pt)
ES (1) ES2663836T3 (pt)
IL (1) IL252174B (pt)
MX (1) MX2017006110A (pt)
NZ (1) NZ732704A (pt)
PL (1) PL3180005T3 (pt)
WO (1) WO2016078921A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115209881A (zh) 2020-03-03 2022-10-18 活跃生物技术有限公司 用于组合疗法的他喹莫德或其药学上可接受的盐
IL300068A (en) 2020-07-23 2023-03-01 Univ Erasmus Med Ct Rotterdam S100 proteins as new therapeutic targets in myeloproliferative catalysis
JP2024503372A (ja) 2021-01-18 2024-01-25 アクティブ バイオテック エイビー 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩
IL308542A (en) 2021-05-25 2024-01-01 Active Biotech Ab Multiparticles of tesquinimod and their use
WO2023275248A1 (en) 2021-07-02 2023-01-05 Active Biotech Ab A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
JP5881691B2 (ja) 2010-07-09 2016-03-09 アクティブ バイオテック エイビー キノリン−３−カルボキサミドの製造方法
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers

Also Published As

Publication number Publication date
ES2663836T3 (es) 2018-04-17
CA2967112C (en) 2023-05-16
NZ732704A (en) 2022-01-28
EA201791099A1 (ru) 2017-10-31
US10300053B2 (en) 2019-05-28
EP3180005A1 (en) 2017-06-21
EP3180005B1 (en) 2017-12-27
EA031643B1 (ru) 2019-01-31
BR112017009854B1 (pt) 2022-08-23
KR102525805B1 (ko) 2023-04-25
AU2015348778A1 (en) 2017-06-29
CN107072989A (zh) 2017-08-18
JP2017534652A (ja) 2017-11-24
AU2015348778B2 (en) 2020-12-24
PL3180005T3 (pl) 2018-06-29
CN107072989B (zh) 2020-07-03
JP6715833B2 (ja) 2020-07-01
IL252174A0 (en) 2017-07-31
US20170319568A1 (en) 2017-11-09
IL252174B (en) 2021-02-28
KR20170083121A (ko) 2017-07-17
CA2967112A1 (en) 2016-05-26
MX2017006110A (es) 2017-07-27
WO2016078921A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
TW201613872A (en) IRAK4 inhibiting agents
GT201700185A (es) Inhibidores selectivos de bace1
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
BR112015032718A2 (pt) composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
MA39749A (fr) Dérivés de pipéridine-dione
EA201791304A1 (ru) Производные изохинолина для лечения вич
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
AU2015352440B2 (en) Compounds
BR112017009854A2 (pt) composto, uso de um composto, e, método para tratamento de leucemia.
BR112017000303A2 (pt) métodos para o tratamento de hipotensão
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2015002358A1 (es) Compuestos bicíclicos.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201591709A1 (ru) 5-бром-индирубины
EA201691493A1 (ru) Замещенные n-арилпиридиноны
BR112017002139A2 (pt) ?método para preparar um composto?
BR112017016396A2 (pt) composto, composição farmacêutica, uso de um composto, e, método.
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
BR112015022576A2 (pt) produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
BR112018071123A2 (pt) (+)-azasetron para uso no tratamento de distúrbios de ouvido

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2015, OBSERVADAS AS CONDICOES LEGAIS